Association of circulating C-reactive protein and interleukin-6 with longevity into the 80s and 90s: The Rancho Bernardo Study.

CONTEXT Few studies have examined whether the inflammatory markers IL-6 and C-reactive protein (CRP) are associated with exceptional longevity. OBJECTIVE Our objective was to determine the association of serum CRP and IL-6 with adult lifespan. DESIGN, SETTING, AND PARTICIPANTS This was a prospective, population-based study of 610 men and 743 postmenopausal women, mean age 73 yr, who had serum IL-6 and CRP measurements at baseline (1984-1987) and who were followed for mortality for up to 23 yr (through 2008). Participants must have been old enough at baseline (57 yr) to have the potential to achieve age 80 during follow-up. MAIN OUTCOME MEASURES Relative survival time and age at death (lifespan) were assessed. RESULTS During follow-up, overall mortality was 69%. After adjustment for cardiovascular disease risk factors, in men, each sd increase in IL-6 was associated with a 15% decrease in survival time and 0.94-yr shorter lifespan (P < 0.001); corresponding values for CRP were a 12% decrease in survival time and a 1.00-yr reduction in lifespan (P < 0.001). Among women not using estrogen therapy (n = 532), survival time decreased 7% per sd higher IL-6 and lifespan was 1.35 yr shorter (P < 0.001). IL-6 was not related to lifespan among women using estrogen. CRP levels were not significantly associated with survival time or lifespan in women regardless of estrogen status. CONCLUSIONS Higher levels of inflammatory markers predicted reduced survival time and shorter lifespan among older men, whereas only IL-6 was associated with longevity in postmenopausal women and only among those not using estrogen.

[1]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[2]  M McGue,et al.  Longevity is moderately heritable in a sample of Danish twins born 1870-1880. , 1993, Journal of gerontology.

[3]  A. Aljada,et al.  Insulin Inhibits Intranuclear Nuclear Factor κB and Stimulates IκB in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect? , 2001 .

[4]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[5]  J. Danesh,et al.  C-reactive protein and coronary disease: is there a causal link? , 2009, Circulation.

[6]  L. Kuller,et al.  Inflammation biomarkers and near-term death in older men. , 2007, American journal of epidemiology.

[7]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[8]  S. Davis,et al.  New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  T. Takebayashi,et al.  Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[11]  C. Bouchard,et al.  Sex differences in inflammatory markers: what is the contribution of visceral adiposity? , 2009, The American journal of clinical nutrition.

[12]  K. Grote,et al.  How much is too much? Interleukin-6 and its signalling in atherosclerosis , 2009, Thrombosis and Haemostasis.

[13]  L. Ferrucci,et al.  Inflammation and Race and Gender Differences in Computerized Tomography‐measured Adipose Depots , 2009, Obesity.

[14]  V. Salomaa,et al.  C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality , 2006, Thrombosis and Haemostasis.

[15]  W. Leifert,et al.  Cardiovascular biology of interleukin-6. , 2009, Current pharmaceutical design.

[16]  Claudio Franceschi,et al.  The Genetics of Human Longevity , 2006, Annals of the New York Academy of Sciences.

[17]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[18]  L. Kuller,et al.  Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  J. Gauldie.  Inflammation and the aging process: devil or angel. , 2007, Nutrition reviews.

[20]  P. Ridker,et al.  Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. , 2010, Journal of vascular surgery.

[21]  S. Cummings,et al.  Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. , 2004, Diabetes care.

[22]  Shahrul Mt-Isa,et al.  Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[23]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[24]  James W. Vaupel,et al.  The heritability of human longevity: A population-based study of 2872 Danish twin pairs born 1870–1900 , 1996, Human Genetics.

[25]  Peter Libby,et al.  Inflammation in Atherosclerosis : From Vascular Biology to Biomarker Discovery and Risk Prediction , 2007 .

[26]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[27]  Diane Catellier,et al.  C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. , 2002, American heart journal.

[28]  L. Kuller,et al.  The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. , 2001, Diabetes.

[29]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[30]  J. Manson,et al.  C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[31]  S. Rubin,et al.  Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.

[32]  William R. Swindell,et al.  Accelerated failure time models provide a useful statistical framework for aging research , 2009, Experimental Gerontology.

[33]  P. Ridker,et al.  C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference? , 2006, Circulation.

[34]  R. Garg,et al.  Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. , 2003, Current drug targets.

[35]  L. Ferrucci,et al.  Biomarkers of Inflammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease: A Cohort Study , 2008, Annals of Internal Medicine.

[36]  P. Ridker.  Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. , 2007, Nutrition reviews.

[37]  C. Kawas,et al.  High Levels of Serum C‐Reactive Protein Are Associated with Greater Risk of All‐Cause Mortality, but Not Dementia, in the Oldest‐Old: Results from The 90+ Study , 2009, Journal of the American Geriatrics Society.

[38]  T. Lehtimäki,et al.  Interleukin-1 receptor antagonist, interleukin-6, and C-reactive protein as predictors of mortality in nonagenarians: the vitality 90+ study. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[39]  T. Strandberg,et al.  C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  A A Schäffer,et al.  Heritability of life span in the Old Order Amish. , 2001, American journal of medical genetics.